Form 4: Allarity Therapeutics Officer Converts RSUs, Sells Shares

Allarity Therapeutics' President and Chief Development Officer, Jeremy R. Graff, converted restricted stock units into common stock and subsequently sold a portion to cover tax obligations.

Summary

• Jeremy R. Graff, President and Chief Development Officer, converted 39,494 Restricted Stock Units (RSUs) into common stock on September 30, 2025.
• Following the conversion, 14,613 shares of common stock were disposed of at a price of $1.58 per share to satisfy tax withholding obligations.
• After these transactions, Graff directly beneficially owns 24,881 shares of common stock and 223,430 Restricted Stock Units.
• The remaining 223,430 RSUs are from grants on September 30, 2024 (118,483 units) and January 22, 2025 (144,441 units), vesting in three equal annual installments starting on the first anniversary of each grant date.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction involving RSU vesting and a tax-related sale. While there's a sale of shares, it's for tax purposes and the officer retains a substantial equity interest, indicating continued alignment. This is a neutral to slightly positive event as it reflects planned compensation.

Positives

• The conversion of Restricted Stock Units indicates a vesting event, which is a planned compensation component for the officer.
• The officer retains a significant number of shares (24,881) and unvested RSUs (223,430) after the transaction, indicating continued alignment with shareholder interests.

Negatives

• A portion of the acquired shares (14,613) was sold, which reduces the officer's direct equity stake in the company.

Future Outlook

The remaining 223,430 Restricted Stock Units will vest in three equal annual installments beginning on the first anniversary of their respective grant dates (September 30, 2024, and January 22, 2025).

Industry Context

This is a routine insider transaction related to executive compensation and does not directly reflect broader industry trends. It's a standard part of executive equity incentive plans.

Related Party Transactions

• Jeremy R. Graff, an officer of Allarity Therapeutics, Inc., engaged in transactions involving the conversion of Restricted Stock Units and the sale of common stock to cover tax obligations.

Stakeholder Impact

• Shareholders: The transaction reflects a planned compensation event for an executive. The sale of shares for tax purposes is a common practice and does not necessarily indicate a lack of confidence. The officer retains significant equity.

Next Steps

• Future vesting of the remaining 223,430 Restricted Stock Units in three equal annual installments, starting from the first anniversary of their grant dates (September 30, 2024, and January 22, 2025).

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where an executive converted Restricted Stock Units and sold a portion to cover tax liabilities. Such transactions are standard components of executive compensation and do not typically signal a change in company fundamentals or management's outlook. The executive retains a substantial equity position, maintaining alignment with shareholder interests. Therefore, the filing itself does not provide new information warranting a change in investment thesis, suggesting a 'hold' recommendation.

Keywords

Allarity Therapeutics, ALLR, Jeremy R. Graff, Form 4, SEC Filing, Insider Trading, Restricted Stock Units, RSU Conversion, Stock Sale, Officer Compensation, Equity Ownership